Xilio Therapeutics, Inc. (XLO): Total Assets
$154.69M
As of 2025-12-31
$154.25M
As of 2026-06-30
+3.6%
3-year compound annual growth
+33.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $154.69M | +117.6% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $71.08M | +16.7% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $60.93M | -56.2% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $139.16M | -36.2% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $218.06M | +500.4% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $36.32M | n/a | 2022-03-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $154.69M | +117.6% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $25.34M | +1.8% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $76.82M | +1.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $160.43M | +58.2% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $638.50M | +81.3% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $28.56M | +29.2% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $596.19M | +30.6% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $668.19M | -10.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
Compare XLO, INBP, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗